CLINUVEL says it has met its recruitment target in its Phase 3 trial (CUV105) of SCENESSE (afamelanotide) in vitiligo, with more than 200 patients enrolled. …
CLINUVEL recruits 200 patients for Phase 3 vitiligo trial of SCENESSE
May 7, 2025 Australian Biotech
Latest Video
New Stories
-
Percheron Therapeutics launches bonus loyalty option offer
May 7, 2025 - - Australian Biotech -
OncoSil Medical reports positive results of pancreatic cancer analysis
May 7, 2025 - - Australian Biotech -
CLINUVEL recruits 200 patients for Phase 3 vitiligo trial of SCENESSE
May 7, 2025 - - Australian Biotech -
Pharmacy Guild calls for standardisation of access to asthma treatment
May 6, 2025 - - Latest News -
Trump administration moves to streamline pharma manufacturing while increasing global inspections
May 6, 2025 - - Latest News -
Sigma delivers continued growth following the completion of Chemist Warehouse merger
May 6, 2025 - - Latest News -
Greg Hunt to chair new telehealth sector working group
May 6, 2025 - - Latest News